Verona Pharma plc — Director's Dealing 2023

Sep 5, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-09-01

Reporting Person: ACKERMANN CHRISTINA (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-01	Share Options (Right to Buy)	$2.43	A	144000	Acquired	2033-08-31	Ordinary Shares (144000)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The option vests and becomes exercisable as to one-third of the underlying options on September 1, 2024 and the remainder in eight equal quarterly installments over the two years thereafter.